Navigation Links
HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice
Date:1/10/2008

NEW YORK, January 10 /PRNewswire-FirstCall/ -- HealthCare Technologies Ltd., (the "Company") today announced that it received a letter dated January 7, 2008 from the Staff of the Listing Qualifications Department (the "Staff Determination") of The NASDAQ Stock Market LLC, which indicated that because the Staff believes that the Company's Plan of Arrangement with NexGen Biofuels, Inc., which closed on December 31, 2007, constituted a reverse merger, the surviving entity is required to submit an initial listing application and satisfy Nasdaq's initial listing standards. On September 7, 2007, NexGen Biofuels, Ltd. submitted its listing application. However, the application was not approved because, among other things, the Company did not meet the minimum $4 bid price requirement for initial listing. Accordingly, the Company's securities will be delisted from The NASDAQ Stock Market. In that regard, unless the Company requests an appeal of this determination, NASDAQ will suspend trading of the Company's securities on the Capital Market at the opening of business on January 16, 2008.

In response, the Company intends to timely request a hearing before a NASDAQ Listing Qualifications Panel to address the Staff Determination and seek continued listing in accordance with applicable NASDAQ rules. The Company's hearing request will stay any delisting action pending the issuance of a decision by the Panel following the hearing.

In the event that the Company's appeal is unsuccessful, the Company believes that its ordinary shares will be eligible for trading on the OTC Bulletin Board, subject to the filing of a Form 211 by a market maker.

For more information on NexGen Biofuels, visit http://www.nexgenbiofuels.net

SAFE HARBOR: This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of HealthCare Technologies Ltd. Readers are referred to the documents filed by the company with the Securities and Exchange Commission, specifically the Form 8-K filed on January 7, 2008 that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

FOR: HealthCare Technologies Ltd.

CONTACT: Eran Rotem CFO

+972-3-9277232-3


'/>"/>
SOURCE HealthCare Technologies Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
2. Quest Diagnostics to Speak at the 26th Annual JPMorgan Healthcare Conference
3. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
4. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
5. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
6. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
8. ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
9. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
10. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
11. AutoGenomics Invited to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
(Date:1/19/2017)... , ... January 18, 2017 , ... ... tech innovators, engineers, and scientists from around the world, was today awarded the ... awards program is based entirely on merit and decided upon by a dedicated ...
(Date:1/19/2017)...  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a ... operable and inoperable solid tumor cancers, announced today that ... NW Bio, will present at the Phacilitate Immunotherapy World ... Regency Hotel in Miami, Florida . ... "New Therapeutic Approaches – Expanding the Reach of Cancer ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
(Date:12/20/2016)... 20, 2016 The rising popularity of ... leasing is stoking significant interest in keyless access ... Bluetooth low energy (BLE), biometrics and near-field communication ... wave of wireless technologies in the automotive industry. ... advanced access systems opens the market to specialist ...
Breaking Biology News(10 mins):